Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01624194 · ClinicalTrials.gov registry record · Phase 2
Intranasal Oxytocin Treatment for Social Deficits in Children With Autism
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT01624194: Completed Phase 2 study, sponsored by Stanford University.
NCT01624194 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01624194, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
Autism is a pervasive developmental disorder characterized by core deficits in social behavior and communication, and the presence of repetitive or stereotyped behaviors. It is one of three recognized disorders in the autism spectrum which affects an estimated 1 in 88 children in the United States. At present, pharmacotherapies target only associated features of autism, with no effective drug treatments for the social impairments. Several lines of evidence now suggest that the neuropeptide oxytocin (OT) may be an effective treatment for the core social deficits in autism. Here we will test the effects of twice daily intranasal OT (24 IU) over a 4-week period for enhancing social deficits in male and female children aged 6-12 years with autism. This research has high potential to lead to the development of more effective treatments and earlier interventions for children with autism.
Interventions
- DRUG Placebo
- DRUG Oxytocin nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01624194
The ClinicalTrials.gov registry entry for NCT01624194 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01624194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01624194 about?
NCT01624194 is a clinical study titled "Intranasal Oxytocin Treatment for Social Deficits in Children With Autism". Autism is a pervasive developmental disorder characterized by core deficits in social behavior and communication, and the presence of repetitive or stereotyped behaviors. It is one of three recognized disorders in the autism spectrum which affects an estimated 1 in 88 children in the United States. ...
What is the current status of trial NCT01624194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2012-06. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01624194?
The interventions under investigation include: Placebo (DRUG), Oxytocin nasal spray (DRUG).
Who is sponsoring clinical trial NCT01624194?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.